Corbus Pharmaceuticals Reports $22.97 Million Net Loss in Q1 2026

Corbus Pharmaceuticals Holdings, Inc. reported a net loss of $22.97 million for the first quarter of 2026, compared to a net loss of $16.98 million for the same period in 2025. The company's operating expenses increased to $24.30 million, up from $19.78 million year-over-year, driven primarily by a 27% rise in research and development costs, which totaled $19.82 million. This increase was largely attributed to higher clinical costs associated with the ongoing Phase 1/2 clinical trial for CRB-701 and the initiation of the Phase 1b study for CRB-913. The net loss per share improved slightly to $(1.23) from $(1.39) as the weighted average number of shares outstanding increased significantly due to stock issuance.

In terms of financial position, Corbus reported total current assets of approximately $143.57 million as of March 31, 2026, a decrease from $166.95 million at the end of 2025. The decline was primarily due to a reduction in cash and cash equivalents, which fell to $25.66 million from $28.49 million. The company’s total liabilities decreased to $18.14 million from $20.69 million, reflecting a reduction in accounts payable. Stockholders' equity also saw a decline, dropping to $126.34 million from $147.50 million, largely due to the accumulated deficit increasing to $578.40 million.

Strategically, Corbus has been active in advancing its clinical pipeline, which includes CRB-701, an antibody drug conjugate for treating Nectin-4-expressing tumors, and CRB-913, a cannabinoid inverse agonist for obesity. The company is currently conducting a Phase 1/2 study for CRB-701 and has received fast track designation from the FDA for its use in specific cancer treatments. Additionally, the company has entered into various license agreements, including a significant one with CSPC Megalith Biopharmaceutical Co., Ltd., which involves milestone payments and royalties based on product sales.

Operationally, Corbus has expanded its workforce, contributing to increased personnel-related costs. The company reported a headcount increase, which is reflected in the rise in general and administrative expenses. As of March 31, 2026, the company had approximately $138.2 million in cash, cash equivalents, and investments, which it expects will be sufficient to meet its operational needs for at least the next twelve months. However, the company anticipates the need for additional financing to support ongoing clinical trials and operational expenses, emphasizing the uncertainty surrounding future funding availability.